Clinical Study
Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease
Table 3
Most frequently reported AEs during 3 months of nightly treatment with transdermal rotigotine in the safety population ().
| |||||||||||||||||||||||||||||||||||||||||||||||||
Reported by at least 2 patients overall; patients could report ≥1 AE. |